9/21/2025

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Gilead Sciences, Inc. is one of them. Gilead Sciences, Inc. (NASDAQ:GILD), headquartered in Foster City, California, continues to lead in antiviral and oncology therapies while advancing next-generation biologics through AI integration. Under CEO Daniel O’Day, the […]

Source: Yahoo

9/19/2025

This is our weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the latest in the article series here.

Source: SeekingAlpha

9/18/2025

Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior day's close.

Source: Yahoo

9/18/2025

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Source: Yahoo

9/18/2025

Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the completion of the safety run-in and the determination of recommended Phase 2 dose (RP2D) for its ongoing Phase 1b/2 STARt-002 trial. The study, evaluating Marengo's dual T-cell agonist invikafusp alfa in combination with TRODELVY® (sacituzumab govitecan-hziy), Gilead's approved TROP2-directed antibody-drug c

Source: Yahoo

9/18/2025

SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Sciences, Inc.’s (“Gilead”) 2025 Multi-Channel Conference in Shanghai. Founder, Chairman and CEO Dr. Xie Fangmin was invited as a keynote guest at the event. The award recognizes Fangzhou’s achievements in advancing innovation and digitalization in healthcare, underscoring its shared commitment with Gil

Source: Yahoo

9/17/2025

Gilead Sciences (GILD) reached $112.26 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.

Source: Yahoo

9/17/2025

Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy volunteers is ongoing Data are being presented at the European Academy of Dermatology and Venereology (EADV) Congress SAN FRANCISCO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company’s ongoing rese

Source: Yahoo

9/16/2025

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best drug stocks to buy right now. In a report released on September 12, Simon Baker CFA from Redburn Atlantic maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and set a price target of $143.00. In other news, Gilead Sciences, Inc. (NASDAQ:GILD) announced on August 26 […]

Source: Yahoo

9/16/2025

ATLANTA, September 16, 2025--Lowe’s Companies, Dow, American Express, ConocoPhillips, and AIG secured top honors in the 2025 U.S. Transparency Awards announced today by Labrador Transparency, a leading global communications firm specializing in transparent corporate disclosure documents. The rankings are determined through a rigorous evaluation of corporate disclosure documents and celebrate companies dedicated to building investor and stakeholder trust through clear, concise, and effective comm

Source: Yahoo

9/16/2025

Gilead Sciences has been treading water for the past six months, holding steady at $112.78. The stock also fell short of the S&P 500’s 16.5% gain during that period.

Source: Yahoo

9/15/2025

Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, September 19, 2025, the Index will be rebalanced, and the following changes will be effective.

Source: Yahoo

9/15/2025

Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.

Source: SeekingAlpha

9/15/2025

Building Resilience and Innovation: California’s Pharmaceutical Renaissance California is quietly staging a pharmaceutical renaissance, not of arts or culture this time, but of science, supply chains, and life-changing therapies. As the backbone of biopharma innovation in the U.S., the Golden State is becoming a place of industry transformation, embodied most recently by investments from Amgen […] The post Why California’s biopharma boom is critical for logistics appeared first on FreightWaves.

Source: Yahoo

9/15/2025

Gilead Sciences Inc. stock underperforms Monday when compared to competitors

Source: MarketWatch

9/14/2025

Investing.com -- RBC Capital said the potential departure of Health and Human Services Secretary Robert F. Kennedy Jr. could have wide-ranging implications for the biotech sector, with both winners and losers across therapeutic areas.

Source: Yahoo

9/13/2025

Stay ahead with Wall Street Week Ahead: key economic data, earnings reports, IPOs, and market forecasts for next week.

Source: SeekingAlpha

9/13/2025

Gilead Sciences Inc. (NASDAQ:GILD) is an American biopharmaceutical company that researches, develops, and sells innovative medicines for life-threatening diseases, focusing on HIV/AIDS, viral hepatitis, cancer, COVID-19, and inflammation. It will ...

Source: Yahoo

9/12/2025

Gilead Sciences Inc. stock underperforms Friday when compared to competitors

Source: MarketWatch

9/11/2025

In the latest trading session, Gilead Sciences (GILD) closed at $117.86, marking a +2.26% move from the previous day.

Source: Yahoo